Learning Objectives

1. Describe the potential benefits of pharmacogenomic (PGX) testing in guiding psychiatric medication selection, including lowering odds for adverse effects, and improving safety from otherwise unidentified drug-drug-gene interactions.
2. Identify the limitations and challenges associated with PGX testing in psychiatry, such as low evidence for improved antidepressant effectiveness, insurance coverage and patient direct cost  
3. Understand core recommendations of current clinical guidelines for PGX testing in prescribing psychiatric medications
4. Summarize evidence supporting the use of pharmacogenomic testing in psychiatry, and formulate strategies for integrating test results into shared decision-making with patients.